



**APRIL 2023**

## Shift Pharmaceuticals Receives Phase I SBIR Funding for Treatment of CMT1A

Shift Pharmaceuticals is pleased to announce the Company has received funding from the National Institute of Neurological Disorders and Stroke for our development program in CMT1A titled “Development of a novel ASO-based therapeutic for CMT1A”.

This funding comes in the form of a Phase 1 Small Business Innovative Resource (SBIR) grant.

### **ABOUT THE NATIONAL INSTITUTES OF HEALTH**

The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the nation’s medical research agency — making important discoveries that improve health and save lives. “The research reported in this release will be supported by the National Institute Of Neurological Disorders And Stroke of the National Institutes of Health under Award Number R43NS125717. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”

### **ABOUT SHIFT PHARMACEUTICALS**

Columbia, MO; Overland Park, KS – Shift Pharmaceuticals (a privately held company) is developing Antisense Oligonucleotides as drug candidates for a variety of genetic disorders. Rather than alleviating certain disease side effects, these molecules “SHIFT” the body’s natural protein production back into alignment effectively addressing the core cause of the disease. Our two lead programs (for the treatment of adult Spinal Muscular Atrophy and Charcot-Marie-Tooth Syndrome type 1A) address genetic disorders of the peripheral nervous system. To date, Shift has received research funding from the NIH, CDMRP, CMTRF, and numerous other private foundations.

### **CONTACT:**

Shift Pharmaceuticals

Dr. Steve O’Connor, CEO

(626) 893-2514

[steve.oconnor@shiftpharmaceuticals.com](mailto:steve.oconnor@shiftpharmaceuticals.com)